These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28473254)

  • 1. PDK1: At the crossroad of cancer signaling pathways.
    Gagliardi PA; Puliafito A; Primo L
    Semin Cancer Biol; 2018 Feb; 48():27-35. PubMed ID: 28473254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
    Maurer M; Su T; Saal LH; Koujak S; Hopkins BD; Barkley CR; Wu J; Nandula S; Dutta B; Xie Y; Chin YR; Kim DI; Ferris JS; Gruvberger-Saal SK; Laakso M; Wang X; Memeo L; Rojtman A; Matos T; Yu JS; Cordon-Cardo C; Isola J; Terry MB; Toker A; Mills GB; Zhao JJ; Murty VV; Hibshoosh H; Parsons R
    Cancer Res; 2009 Aug; 69(15):6299-306. PubMed ID: 19602588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.
    De Luca A; Maiello MR; D'Alessio A; Pergameno M; Normanno N
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S17-27. PubMed ID: 22443084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway.
    Lu Z; Cox-Hipkin MA; Windsor WT; Boyapati A
    Mol Cancer Res; 2010 Mar; 8(3):421-32. PubMed ID: 20197379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotactic activation of Dictyostelium AGC-family kinases AKT and PKBR1 requires separate but coordinated functions of PDK1 and TORC2.
    Liao XH; Buggey J; Kimmel AR
    J Cell Sci; 2010 Mar; 123(Pt 6):983-92. PubMed ID: 20200230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDK1: A signaling hub for cell migration and tumor invasion.
    Gagliardi PA; di Blasio L; Primo L
    Biochim Biophys Acta; 2015 Dec; 1856(2):178-88. PubMed ID: 26238471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K-PDK1 connection: more than just a road to PKB.
    Vanhaesebroeck B; Alessi DR
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):561-76. PubMed ID: 10698680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination.
    Di Blasio L; Gagliardi PA; Puliafito A; Primo L
    Cancers (Basel); 2017 Mar; 9(3):. PubMed ID: 28287465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery.
    Watanabe S; Matsumoto T; Oda M; Yamada K; Takagi J; Taguchi K; Kobayashi T
    Pflugers Arch; 2016 Apr; 468(4):667-77. PubMed ID: 26577585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-SMA-Cre-mediated excision of PDK1 reveals an essential role of PDK1 in regulating morphology of cardiomyocyte and tumor progression in tissue microenvironment.
    Qian XJ; Li XL; Xu X; Wang X; Feng QT; Yang CJ
    Pathol Biol (Paris); 2015 Apr; 63(2):91-100. PubMed ID: 25601552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer.
    Tan J; Lee PL; Li Z; Jiang X; Lim YC; Hooi SC; Yu Q
    Cancer Cell; 2010 Nov; 18(5):459-71. PubMed ID: 21075311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tripping on TRIB3 at the junction of health, metabolic dysfunction and cancer.
    Mondal D; Mathur A; Chandra PK
    Biochimie; 2016 May; 124():34-52. PubMed ID: 26855171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
    Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
    Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
    Harris TK
    IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second AKT: the rise of SGK in cancer signalling.
    Bruhn MA; Pearson RB; Hannan RD; Sheppard KE
    Growth Factors; 2010 Dec; 28(6):394-408. PubMed ID: 20919962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.